CN108719998A - An oral dietary supplement for the treatment of osteoarthritis - Google Patents
An oral dietary supplement for the treatment of osteoarthritis Download PDFInfo
- Publication number
- CN108719998A CN108719998A CN201710269128.1A CN201710269128A CN108719998A CN 108719998 A CN108719998 A CN 108719998A CN 201710269128 A CN201710269128 A CN 201710269128A CN 108719998 A CN108719998 A CN 108719998A
- Authority
- CN
- China
- Prior art keywords
- magnesium
- meal supplement
- supplement medicament
- medicament
- meal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 14
- 235000015872 dietary supplement Nutrition 0.000 title abstract 3
- 239000003814 drug Substances 0.000 claims abstract description 47
- 239000011777 magnesium Substances 0.000 claims abstract description 33
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 28
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000013589 supplement Substances 0.000 claims description 37
- 235000012054 meals Nutrition 0.000 claims description 32
- 229940091250 magnesium supplement Drugs 0.000 claims description 27
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 11
- 230000037213 diet Effects 0.000 claims description 9
- 235000005911 diet Nutrition 0.000 claims description 9
- 239000000395 magnesium oxide Substances 0.000 claims description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 6
- 230000000975 bioactive effect Effects 0.000 claims description 6
- 210000002744 extracellular matrix Anatomy 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 4
- 229960003390 magnesium sulfate Drugs 0.000 claims description 4
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- MHJAJDCZWVHCPF-UHFFFAOYSA-L dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000000122 growth hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 239000001755 magnesium gluconate Substances 0.000 claims description 2
- 229960003035 magnesium gluconate Drugs 0.000 claims description 2
- 235000015778 magnesium gluconate Nutrition 0.000 claims description 2
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 claims description 2
- 239000000626 magnesium lactate Substances 0.000 claims description 2
- 229960004658 magnesium lactate Drugs 0.000 claims description 2
- 235000015229 magnesium lactate Nutrition 0.000 claims description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims description 2
- 239000004137 magnesium phosphate Substances 0.000 claims description 2
- 229960002261 magnesium phosphate Drugs 0.000 claims description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 claims description 2
- 235000010994 magnesium phosphates Nutrition 0.000 claims description 2
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- OMEBXAYMRCYOTB-UHFFFAOYSA-N [P].OCC(O)CO Chemical compound [P].OCC(O)CO OMEBXAYMRCYOTB-UHFFFAOYSA-N 0.000 claims 1
- XNEYCQMMVLAXTN-UHFFFAOYSA-N carbonic acid;magnesium Chemical compound [Mg].OC(O)=O XNEYCQMMVLAXTN-UHFFFAOYSA-N 0.000 claims 1
- 229960005336 magnesium citrate Drugs 0.000 claims 1
- 235000002538 magnesium citrate Nutrition 0.000 claims 1
- 239000004337 magnesium citrate Substances 0.000 claims 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 abstract description 13
- 206010007710 Cartilage injury Diseases 0.000 abstract description 3
- 230000008422 cartilage matrix degradation Effects 0.000 abstract description 3
- 230000008355 cartilage degradation Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000007850 degeneration Effects 0.000 description 6
- 210000000629 knee joint Anatomy 0.000 description 4
- 229940126701 oral medication Drugs 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 210000004439 collateral ligament Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 229960004590 diacerein Drugs 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000011742 magnesium glycerophosphate Substances 0.000 description 1
- 235000001130 magnesium glycerophosphate Nutrition 0.000 description 1
- BHJKUVVFSKEBEX-UHFFFAOYSA-L magnesium;2,3-dihydroxypropyl phosphate Chemical compound [Mg+2].OCC(O)COP([O-])([O-])=O BHJKUVVFSKEBEX-UHFFFAOYSA-L 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003044 randomized block design Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000007886 soft shell capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004353 tibial menisci Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an oral dietary supplement medicament for treating osteoarthritis. The dietary supplement contains magnesium, reduces cartilage damage in the rat OA model, and is effective in reducing cartilage matrix degradation, reducing cartilage surface wear, and delaying cartilage degradation.
Description
Technical field
The oral diet that the present invention relates to a kind of for treating osteoarthritis supplements medicament.
Technical background
Osteoarthritis (Osteoarthritis, OA) is one kind with cartilage degeneration, Subchondral bone sclerosis and spur shape
As the joint degenerative disease of main feature, and it is that it mainly faces with movable posterior joint pain, limitation of activity and dysarthrasis
Bed performance, often involves weight-bearing joints.China's epidemiological investigation shows that the illness rate of OA is more than in over-65s crowd
50%, there are a degree of limitation of movement, 25% OA patient's daily life is significantly affected about 80% OA patient, and
Annual expense for treating OA or up to 150,000,000,000 yuan.In U.S. 50 years old or more crowd, the disability rate of OA occupies all diseases
In second, be only second to angiocardiopathy.With the increase of global aging populations and population of being obese, the illness rate of OA is also
It will further improve.
Currently, there is no the active drug for the treatment of OA both at home and abroad, newest world OA authority's guide clearly proposes that many is always
Since be widely used in treating the drug of OA, such as hyaluronic acid, Glucosamine, chondroitin sulfate and diacerein, due to
The appearance of the evidence-based medical of newest high quality, validity worldwide cause extensive dispute or even quilt
Regard as uncertain therapeutic efficacy it is fixed or do not recommend (McAlindon T E etc., Osteoarthritis and Cartilage,
2014,22 (3):363‐388).Treatment for early metaphase OA can only often be played the role of relieving pain and improving function.By
It is mostly the middle-aged and the old in OA patient, is often accompanied by other systemic diseases, such as digestive system and disease of cardiovascular system, and the one of OA
Line medicine (remission) such as non-steroid anti-inflammatory drug (Non-steroidal antiinflammatory drugs,
NSAIDs use) easily causes the increase of gastrointestinal side effect and cardiovascular event risk, it would therefore be highly desirable to explore in morning
The safely and effectively medicine of phase OA patient.
Magnesium ion (Magnesium2+, Mg) and it is the second abundant, extracellular 4th abundant cation in human body cell, as
The coenzyme of internal more than 300 kinds of enzymes, durings the synthesis of the energetic supersession of body, nucleic acid and protein and inflammatory and immune response etc.
It plays an important role.The past epidemiological study shows that diet Mg intakes level and serum Mg ion concentrations are in OA illness
Negatively correlated (Zeng C etc., The Journal of rheumatology, 2015,42 (7):1231‐1236；Zeng C etc.,
PloS one, 2015,10 (5):e0127666).Meanwhile Mg be also proved relieve pain, Saving cortilage cartilage and inhibition
Abnormal mineralization etc. play an important role (Fioravanti etc., Int J Biometeorol, 2014,58：79‐86；
Pfister etc., Antimicrob Agents Ch, 2007,51：1022‐1027；Calo etc., Am J Nephrol, 2000,20：
347-350), prompt Mg may be the protection sexual factor of OA.In addition, there will be research confirms that joint cavity injection magnesium sulfate can significantly drop
Low rat OA models cartilage damage degree (Lee etc., Osteoarthr and Cartilage, 2009,17：1485‐1493).
Therefore, Mg may can be used as auxiliary treatment of the drug for OA.
However, the mode of articular cavity administration is complex, and joint puncture can also increase pain and the companion of patient repeatedly
There is the possibility of the infection of joint, therefore joint cavity injection magnesium sulfate on treatment OA has certain limitation, needs exploitation easier
Magnesium elements and its administering mode of compound achieve the purpose that treat OA.
Without description oral route intake magnesium elements and its compound for treating OA in the patent and publication of the past
Purposes.In field of medicaments, still it is badly in need of obtaining curative for effect for OA and Small side effects therapeutic agents.
Invention content
The present invention is directed to overcome the deficiencies of the prior art and provide a kind of oral diet supplement medicine for treating osteoarthritis
Agent.
The meal supplement medicament for treating osteoarthritis, which is characterized in that contain in the meal supplement medicament
The content of magnesium, the magnesium is 5g/kg to 100g/kg.
Preferably, the magnesium is originated from magnesium-containing compound.
Preferably, the magnesium-containing compound includes magnesia, magnesium carbonate, magnesium chloride, L- magnesium threonates, magnesium sulfate, lemon
Sour magnesium, magnesium gluconate, magnesium lactate, magnesium monohydrogen phosphate, magnesium phosphate, magnesium glycerophosphate.
Preferably, the magnesium-containing compound is magnesia.
Preferably, in the meal supplement medicament also contain be useful for enhancing extracellular matrix molecule, wherein magnesium be used for
The weight ratio for enhancing the molecule of extracellular matrix is 1:0.2 to 1:1.
Preferably, the molecule for enhancing extracellular matrix is collagen or glycosaminoglycan.
Preferably, also contain pharmacology and/or bioactive substance, wherein magnesium and medicine in the oral diet supplement medicament
Of science and/or bioactive substance weight ratio is 1:0.2 to 1:1.
Preferably, the pharmacology and/or bioactive substance are growth factor, hormone and/or vitamin.
Preferably, also contain auxiliary material in the meal supplement medicament.
Preferably, the administering mode of the meal supplement medicament is oral.
The invention will be further described below：
The meal supplement medicament of the present invention includes any kind of food, clinical nutrition product and health products.According to this hair
Bright meal supplement medicament can further include protectiveness glue matter, adhesive, film forming agent, encapsulant/material, coating, breast
Agent, surfactant, solubilizer, adsorbent, supporting agent, filler, auxiliary compounds, dispersant, wetting agent, processing aid, stream
Dynamic reagent, odor mask, weighting agent, antioxidant and antiseptic etc..
Other than pharmaceutically acceptable supporting agent and magnesium and its compound, meal supplement medicament of the invention can be wrapped further
Containing conventional pharmacy additive and adjuvant, excipient or diluent, flavoring agent, preservative, stabilizer, emulsifier, buffer, profit
Lubrication prescription, colorant, wetting agent, filler etc..The carrier material can be adapted for organic or electrodeless inert carrier of oral medication
Material.
Meal supplement medicament according to the present invention and pharmaceutical composition can be any forms commonly used in oral medication,
For example, following solid form, additive/replenishers of such as food, meal premix, tablet, pill, particle, dragee,
The effervescent formulation of capsule and such as powder and tablet；Following liquid form, such as solution, lotion or suspension, such as beverage, paste
Object or oleaginous suspension.Paste can be filled into hard shell or soft shell capsule.
In one embodiment of the present of invention, the cartilage damage of rat OA models can be mitigated by having proven to the supplement of magnesia mixture in diet
Degree is effective in reducing cartilage matrix degradation, the reduction cartilage surface degree of wear and delaying cartilage degeneration.
The shortcomings that presently commercially available drug is not present in the meal supplement medicament or combination of oral medication of the present invention, in particular,
Compared with current OA treats common drug, have the following advantages that：
1) Oral administration makes OA patient have better compliance and more selectivity；
2) curative for effect to OA；
3) there is no apparent side effect；
4) expense is lower.
Description of the drawings
Fig. 1 is that Rat Right knee joint is sliced the fast green coloration result of sarranine.
Specific implementation mode
The zoopery of embodiment magnesium elements and its compound meal supplement pharmaceutical treatment osteoarthritis curative effect is verified
1 experiment material and method
1.1 drugs and reagent
Normal rats feed (magnesium element content 0.255g/kg)
The rat feed (magnesium element content 2.55g/kg) of magnesia meal supplement medicament is added
1.2 experimental animal
Bull Sprague-Dawley (SD) rat (weight 500g or so)
1.3 experimental method
1.3.1 operation modeling
Knee OA models are built by the right medial collateral ligament of row, anterior cruciate ligament-transection art and medial meniscus resection.
The model, which has been verified, can induce knee osteoarthritis, represent the good example of experimental degenerative osteoarthritis, can be used for
Pharmacological evaluation is carried out to the drug surveyed.
1.3.2 grouping and administration
Take RANDOMIZED BLOCK DESIGN that rat is randomly divided into 2 groups according to weight after modeling：
1) full diet group, the postoperative same day give normal rats forage feed, week for 7 weeks；
2) meal supplement pharmaceutical treatment group, the rat feed that magnesia meal supplement medicament is added in the postoperative same day are fed
It supports, week for 7 weeks；
1.3.3 evaluation method
Take within postoperative 7th week right side knee cartilage preparation of specimen pathological section, the fast green dyeing of row sarranine, using improvement
Two groups of rat knee joints cartilage degeneration degree are assessed in Mankin scorings (table 1).This method can wear cartilage surface, is soft
Bone cell proliferation, cartilage matrix degradation carry out overall merit, react the degree of degeneration of cartilage.The higher reaction cartilage degeneration journey of scoring
Degree is heavier.
Table 1：Improve Mankin scorings
2. experimental result
Two groups of Rat Right knee joint Mankin appraisal results such as tables 2.
Table 2：Cartilaginous tissue improves Mankin pathological scores
Statistical analysis shows that the Mankin scorings of magnesia meal supplement pharmaceutical treatment group are less than full diet group, knee joint stock
Outside difference has a statistical significance (P < 0.05) on the inside of bone condyle and in tibial plateau, and difference is close to statistics on the outside of condyle of femur
Meaning (P=0.060).
The above result shows that magnesia meal supplement medicament has the function of good alleviation cartilage degeneration in embodiment.Cause
This, meal supplement containing magnesium of the invention medicament or combination of oral medication treatment osteoarthritis are effective.
Claims (10)
1. a kind of meal supplement medicament for treating osteoarthritis, which is characterized in that contain magnesium in the meal supplement medicament,
The content of the magnesium is 5g/kg to 100g/kg.
2. meal supplement medicament as described in claim 1, which is characterized in that the magnesium is originated from magnesium-containing compound.
3. meal supplement medicament as claimed in claim 2, which is characterized in that the magnesium-containing compound includes magnesia, carbonic acid
Magnesium, magnesium chloride, L- magnesium threonates, magnesium sulfate, magnesium citrate, magnesium gluconate, magnesium lactate, magnesium monohydrogen phosphate, magnesium phosphate, glycerine phosphorus
Sour magnesium.
4. meal supplement medicament as claimed in claim 3, which is characterized in that the magnesium-containing compound is magnesia.
5. meal supplement medicament as described in claim 1, which is characterized in that also contain in the meal supplement medicament and be useful for increasing
The weight ratio of the molecule of strong extracellular matrix, wherein magnesium and the molecule for enhancing extracellular matrix is 1:0.2 to 1:1.
6. meal supplement medicament as claimed in claim 5, which is characterized in that the molecule for enhancing extracellular matrix is
Collagen or glycosaminoglycan.
7. meal supplement medicament as described in claim 1, which is characterized in that also contain medicine in the oral diet supplement medicament
Of science and/or bioactive substance, wherein magnesium are 1 with the weight ratio of pharmacology and/or bioactive substance:0.2 to 1:1.
8. meal supplement medicament as claimed in claim 7, which is characterized in that the pharmacology and/or bioactive substance are
Growth factor, hormone and/or vitamin.
9. meal supplement medicament as described in any one of claim 1 to 7, which is characterized in that in the meal supplement medicament also
Contain auxiliary material.
10. meal supplement medicament as claimed in claim 9, which is characterized in that the administering mode of the meal supplement medicament is
It is oral.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710269128.1A CN108719998A (en) | 2017-04-24 | 2017-04-24 | An oral dietary supplement for the treatment of osteoarthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710269128.1A CN108719998A (en) | 2017-04-24 | 2017-04-24 | An oral dietary supplement for the treatment of osteoarthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108719998A true CN108719998A (en) | 2018-11-02 |
Family
ID=63934150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710269128.1A Pending CN108719998A (en) | 2017-04-24 | 2017-04-24 | An oral dietary supplement for the treatment of osteoarthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108719998A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115315242A (en) * | 2020-04-22 | 2022-11-08 | 株式会社资生堂 | Hyaluronic acid production promoter |
| CN117562869A (en) * | 2023-05-05 | 2024-02-20 | 中南大学湘雅医院 | Magnesium hydroxide nanoparticle for treating arthralgia, preparation method and application thereof |
-
2017
- 2017-04-24 CN CN201710269128.1A patent/CN108719998A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| C. H. LEE ET AL.: "Intra-articular magnesium sulfate (MgSO4) reduces experimental osteoarthritis and nociception: association with attenuation of N-methyl-d-aspartate (NMDA) receptor subunit 1 phosphorylation and apoptosis in rat chondrocytes", 《OSTEOARTHRITIS AND CARTILAGE》 * |
| 丁香园: "美国白人饮食镁摄入可降低膝骨关节炎发生", 《HTTP://RHEUM.DXY.CN/ARTICLE/37666》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115315242A (en) * | 2020-04-22 | 2022-11-08 | 株式会社资生堂 | Hyaluronic acid production promoter |
| CN117562869A (en) * | 2023-05-05 | 2024-02-20 | 中南大学湘雅医院 | Magnesium hydroxide nanoparticle for treating arthralgia, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8778410B2 (en) | Oral or enteral composition useful for recovery of physical functions | |
| US20070292493A1 (en) | Pharmaceutical composition and method for the transdermal delivery of calcium | |
| EP1662908B1 (en) | Composition and method for facilitating bone healing | |
| CN101711786B (en) | Preparation used for relieving osteoarthropathy and enhancing immunity | |
| EP1083915B1 (en) | Compositions comprising molybdenum for enhancing protein anabolism and detoxification | |
| CN108719998A (en) | An oral dietary supplement for the treatment of osteoarthritis | |
| KR20190058346A (en) | Composition comprising chp (cyclo-his pro) for preventing, improving or treating of bone loss related disease | |
| CN108815505A (en) | Improve the composition that middle-aged and the old's bone density and osteoarticular function avoid waist-leg from knotting | |
| WO2019134534A1 (en) | Use of e-10-hydroxyl-2-decylenic acid in preparation of medicine or health care product for preventing and treating osteoporosis | |
| CN113082059B (en) | Composition for preventing and treating osteoporosis and preparation method and application thereof | |
| RU2379043C2 (en) | Pharmaceutical composition for prevention and treatment of menopause osteoporosis in women | |
| KR20080087941A (en) | A composition containing the low molecular weight hyaluronic acid for improving skin wrinkles and skin peeling | |
| CN102000110A (en) | Composition used for preventing or treating bone and joint diseases and preparation method thereof | |
| KR20170103380A (en) | Composition For Improving Skin Constitution Between Race | |
| CN106036387A (en) | Super chenopodium quinoa willd nutritional packet for promoting growth of children | |
| KR100597564B1 (en) | Pharmacuetical compositions comprising Eleutheroside E having bone growth-promoting effects | |
| RU2356546C1 (en) | Sygethin-based pharmaceutical structure for osteoporosis prevention and treatment (versions) | |
| AU5778801A (en) | Improvements in effervescent tablet manufacture | |
| CN111012900B (en) | Composition with bone mineral density increasing function and preparation method and application thereof | |
| WO2015040223A1 (en) | Cocoa polyphenols and their use in the treatment or prevention of eosinophilic esophagitis | |
| RU2819538C1 (en) | Formulation of specialized sports nutrition for recovery, including prevention of arthritis and other joint diseases, and inclusion in the anti-age therapy program | |
| WO2023074893A1 (en) | Cartilage regeneration composition | |
| KR20050104091A (en) | Eleutheroside e having bone growth-promoting effects and functional foods or pharmaceutical preparations containing the same | |
| JP2024055799A (en) | Composition for preventing or improving sports injuries | |
| JP2023067857A (en) | Agent for promoting growth of growth plates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181102 |
|
| RJ01 | Rejection of invention patent application after publication |